Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability

Table 4 Stresses scores in the study groups. Values are expressed as Mean (SD)

	Before treatment	After 1 month	P value	After 6 months	P value	After 12 months	P value	Follow-up	P value
Group A Peg-IFN α + RBV + placebo (n = 31)
Work ability index	36.9 ± 5.2	21.4 ± 5.3	<0.01	37.8 ± 5.9	NS	38.7 ± 5.8	NS	39.8 ± 6.7	<0.001
STAI	50.1 ± 7.6	59.2 ± 7.4	<0.01	60.4 ± 7.7	<0.001	58.2 ± 7.4	<0.001	61.4 ± 7.2	<0.001
BDI	30.8 ± 6.9	44.6 ± 6.7	<0.01	46.7 ± 6.8	<0.001	40.9 ± 6.9	<0.001	40.4 ± 6.2	<0.001
Group B Peg IFN α + RBV + Silybin, Vit E, phospholipids (n = 31)
Work ability index	35.4 ± 5.9	30.2 ± 6.2	<0.001	38.4 ± 6.8	NS	40.7 ± 6.1	<0.05	39.8 ± 6.4	<0.05
STAI	50.8 ± 7.9	59.8 ± 7.1	<0.001	50.4 ± 7.2	NS	47.4 ± 7.8	NS	50.6 ± 7.0	NS
BDI	30.7 ± 7.1	48.7 ± 7.8	<0.001	34.6 ± 7.1	NS	30.1 ± 7.2	NS	30.4 ± 6.8	NS

ISSN: 1471-244X